Patients’ safety

• Verfasst von: Moghaddam-Alvandi, Arash [VerfasserIn]
• Verfasst von: Graeser, Viola [VerfasserIn]
• Verfasst von: Westhauser, Fabian [VerfasserIn]
• Verfasst von: Dapunt, Ulrike A. [VerfasserIn]
• Verfasst von: Kamradt, Till [VerfasserIn]
• Verfasst von: Wörner, Stefan M. [VerfasserIn]
• Verfasst von: Schmidmaier, Gerhard [VerfasserIn]
• Titel: Patients’ safety
• Titelzusatz: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use?
• Verf.angabe: Arash Moghaddam, Viola Graeser, Fabian Westhauser, Ulrike Dapunt, Till Kamradt, Stefan M. Woerner, Gerhard Schmidmaier
• E-Jahr: 2016
• Jahr: 7 September 2016
• Umfang: 7 S.
• Fussnoten: Gesehen am 10.07.2020
• Titel Quelle: Enthalten in: Therapeutics and clinical risk management
• Ort Quelle: Albany, Auckland : Dove Medical Press, 2005
• Jahr Quelle: 2016
• Band/Heft Quelle: 12(2016), Seite 1387-1393
• ISSN Quelle: 1178-203X
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1724323946

Abstract

Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use? Arash Moghaddam,1 Viola Graeser,1 Fabian Westhauser,1 Ulrike Dapunt,1 Till Kamradt,1 Stefan M Woerner,2 Gerhard Schmidmaier1 1HTRG - Heidelberg Traume Research Group Center for Orthopedics, Trauma and Spinal Cord Injury, University Hospital Heidelberg, Heidelberg, Germany; 2Department of Internal Medicine and Clinical Chemistry, University Hospital Heidelberg, Heidelberg, Germany Introduction: Osteitis is one of the most serious complications in orthopedic surgery. Expert Tibia Nail (ETN) PROtect™ coated with a biodegradable layer of gentamicin-laden polymer was developed for prophylaxis of osteomyelitis. In systemic administration, gentamicin has only a small therapeutic index and serious side effects; it is potentially nephrotoxic as well as ototoxic. It is not yet known if relevant gentamicin concentrations are released into the systemic circulation after implantation of gentamicin-coated nails. In order to evaluate the patients’ risks profiles and increase patient safety, we measured gentamicin levels in pre- and postoperative serum samples of patients undergoing implantation of ETN PROtect.Methods: Twenty-five patients who received ETN PROtect between March 2012 and August 2014 were included in this study. Collection of blood samples occurred before the operation, at weeks 1-4, 3 and 6 months, and up to 1 year after the implantation. Measurement of gentamicin levels in serum samples was performed at the central laboratory of Heidelberg University Hospital. Additionally, laboratory parameters, C-reactive protein, leukocyte number, urea and creatinine concentrations were analyzed in routine controls before and after operating and assessed for systemic side effects.Results: Over the course of this prospective observational study, we were able to determine that gentamicin-coated nails do not release gentamicin into the systemic circulation above the lowest detectable level of 0.2 mg/dL. There were slight increases in the mean inflammation and renal retention markers, but no gentamicin-associated side effects could be linked to implantation. Furthermore, no allergic reactions could be detected during our study.Conclusion: Our findings suggest that there is no relevant release of gentamicin into the systemic circulation causing a systemic effect, and serious side effects due to gentamicin-coated tibia nails should not be feared. Postoperative monitoring of renal function does not seem necessary because of the implantation of ETN PROtect. Keywords: osteomyelitis, osteitis, pseudoarthrosis, fracture, therapy, ETN PROtect, implant, infection, tibia